Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

322 ARTÍCULOS , VIENDO DEL 151 AL 165

Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis

Boche D, Denham N, Holmes C, Nicoll JA.

Acta Neuropathol. 2010 Sep;120(3):369-84. doi: 10.1007/s00401-010-0719-5. Epub 2010 Jul 15.

Neuroinflammatory processes in Alzheimer's disease

Heneka MT, O'Banion MK, Terwel D, Kummer MP.

J Neural Transm (Vienna). 2010 Aug;117(8):919-47. doi: 10.1007/s00702-010-0438-z. Epub 2010 Jul 15.

Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis

Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, Zhang R, Xu Y, Sun Y, Richardson S, Mackell J.

J Alzheimers Dis. 2010;21(3):843-51. doi: 10.3233/JAD-2010-100078.

Immunotherapy and neuroimmunology in Alzheimer's disease: a perspective from the blood-brain barrier

Banks WA.

Immunotherapy. 2010 Jan;2(1):1-3. doi: 10.2217/imt.09.72.

Inhibition of BACE1 for therapeutic use in Alzheimer's disease

Luo X, Yan R.

Int J Clin Exp Pathol. 2010 Jul 8;3(6):618-28.

[Development of new drugs for Alzheimer's disease]

Tabira T.

Brain Nerve. 2010 Jul;62(7):787-96.

Tau aggregation is a therapeutic target for Alzheimer's disease

Takashima A.

Curr Alzheimer Res. 2010 Dec;7(8):665-9. doi: 10.2174/156720510793611600.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A.

Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.

Statins for the treatment of dementia

McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007514. doi: 10.1002/14651858.CD007514.pub2.

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

Irwin N, Gault V, Flatt PR.

Expert Opin Investig Drugs. 2010 Sep;19(9):1039-48. doi: 10.1517/13543784.2010.513381.

The multifactorial nature of Alzheimer's disease and related therapeutic strategies

do Carmo Carreiras M, Marco-Contelles J.

Curr Pharm Des. 2010;16(25):2765. doi: 10.2174/138161210793176554.

Cell death targets and potential modulators in Alzheimer's disease

Castro RE, Santos MM, Glória PM, Ribeiro CJ, Ferreira DM, Xavier JM, Moreira R, Rodrigues CM.

Curr Pharm Des. 2010;16(25):2851-64. doi: 10.2174/138161210793176563.

Nitric oxide: target for therapeutic strategies in Alzheimer's disease

Fernandez AP, Pozo-Rodrigalvarez A, Serrano J, Martinez-Murillo R.

Curr Pharm Des. 2010;16(25):2837-50. doi: 10.2174/138161210793176590.

Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease

Agostinho P, Cunha RA, Oliveira C.

Curr Pharm Des. 2010;16(25):2766-78. doi: 10.2174/138161210793176572.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias